Pages that link to "Q54616742"
Jump to navigation
Jump to search
The following pages link to Clinicopathological significance and prognostic value of CD133 expression in triple‐negative breast carcinoma (Q54616742):
Displaying 38 items.
- Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells (Q28066297) (← links)
- Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma (Q33574875) (← links)
- Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer (Q33798788) (← links)
- CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer (Q34438511) (← links)
- Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected]. (Q35866920) (← links)
- CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV (Q36030949) (← links)
- Overexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast Cancer (Q36092011) (← links)
- Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis (Q36292530) (← links)
- Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer (Q36441530) (← links)
- CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis (Q36962860) (← links)
- The prognostic role of cancer stem cells in breast tumors (Q37108555) (← links)
- Topoisomerase IIβ mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs (Q37125974) (← links)
- CD133 expression associated with poor prognosis in ovarian cancer (Q37373712) (← links)
- HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. (Q37376195) (← links)
- In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness (Q37399964) (← links)
- Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer (Q37468314) (← links)
- Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors (Q37513954) (← links)
- Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes (Q38007856) (← links)
- CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges (Q38035206) (← links)
- Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery (Q38383345) (← links)
- Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients (Q38949124) (← links)
- Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma (Q38954672) (← links)
- Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. (Q39399161) (← links)
- CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). (Q39473541) (← links)
- Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer". (Q39900695) (← links)
- Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas. (Q40695629) (← links)
- Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer (Q41182171) (← links)
- Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari". (Q41350562) (← links)
- Nanomedicine applications in the treatment of breast cancer: current state of the art. (Q41483629) (← links)
- Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC. (Q41611344) (← links)
- Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis (Q42748057) (← links)
- Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast (Q44473846) (← links)
- Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer (Q58572653) (← links)
- Inadequacy of tissue microarrays for the immunohistochemical detection of cancer stem cells in solid tumors: a viewpoint (Q59011730) (← links)
- Ectopic expression of PLC‐β2 in non‐invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR‐146a (Q63633881) (← links)
- Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events (Q88149003) (← links)
- The Role of Breast Cancer Stem Cell-Related Biomarkers as Prognostic Factors (Q99604857) (← links)
- Property talk:P7452/qualifiers to check (← links | edit)